长春高新：金蓓欣目前销售情况良好 已搭建两百余人的销售团队

Core Viewpoint - Changchun High-tech (000661) reported positive sales performance for its new products during an institutional conference call, highlighting the successful launch and sales of Jin Peixin and Meishiya products in the cancer treatment sector [1] Group 1: Product Launch and Sales Performance - Jin Peixin received approval by the end of June 2025 and began sales in mid-July, achieving sales revenue exceeding 55 million yuan in the third quarter of 2025 [1] - The company has established a sales team of over 200 people and is rapidly increasing its coverage in hospitals and distribution channels [1] Group 2: Market Strategy and Future Plans - The Meishiya product for cancer-related anorexia-cachexia syndrome has generated nearly 100 million yuan in sales revenue in the first three quarters of this year [1] - The company plans to actively promote the sales of related products in conjunction with the progress of national medical insurance negotiations [1]